ADDEX THERAPEUTICS L

ADXN
Delayed Quote. Delayed  - 05/12 11:32:00 am
1.45CHF -2.03%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Number of employees : 27 people.
Sales per Business
20192020
CHF
(in Million)
%CHF
(in Million)
%
Small-molecule Pharmaceutical Products 2.83100% 3.88106.7%
Sales per region
20192020
CHF
(in Million)
%CHF
(in Million)
%
Switzerland 0.0712.5% 0.2667.3%
Managers
Name Title
Timothy Dyer Chief Executive Officer & Director
Lénaic Teyssédou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Raymond George Hill Director
Jake R. Nunn Director
Isaac Manke Director
Jean-Philippe Rocher Head-Discovery Chemistry
Shareholders
Name Equities %
Addex Therapeutics Ltd 15,207,866 30.9%
NEA Management Co. LLC 5,648,690 11.5%
New Leaf Venture Partners LLC 1,897,444 3.85%
Caxton Corp. 1,595,640 3.24%
Credit Suisse Asset Management (Schweiz) AG 1,198,245 2.43%
Laurence W. Lytton 1,188,484 2.41%
Timothy Dyer 435,192 0.88%
Herculis Partners SA 365,137 0.74%
Roger G. Mills 332,501 0.67%
UBS Asset Management Switzerland AG 220,250 0.45%
Company contact information
Addex Therapeutics Ltd.
9, Chemin des Aulx
Plan-les-Ouates
Geneva, Geneve (Geneva) 1202

Phone : +41.22.884.15.55
Fax : +41.22.884.15.56
Web : http://www.addextherapeutics.com
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
ADDEX THERAPEUTICS LTD-33.51%70
MODERNA, INC.46.15%60 177
LONZA GROUP AG-1.83%45 717
IQVIA HOLDINGS INC.28.18%44 017
CELLTRION, INC.-26.18%31 985
SEAGEN INC.-17.37%26 262
CUREVAC N.V.26.25%21 497
HANGZHOU TIGERMED CONSULTING CO.,LTD-5.82%20 472
PHARMARON BEIJING CO., LTD.36.88%20 297
INCYTE CORPORATION-5.30%18 304
PPD, INC.34.69%16 177
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.26.78%16 132
ALNYLAM PHARMACEUTICALS, INC.2.27%15 624
BIO-TECHNE CORPORATION24.91%15 427
ICON PUBLIC LIMITED COMPANY15.02%12 004
PRA HEALTH SCIENCES, INC.37.05%11 139
QIAGEN N.V.-12.02%10 621
ABCELLERA BIOLOGICS INC.-23.66%9 249
NOVAVAX, INC.8.51%8 962
SYNEOS HEALTH, INC.25.13%8 851
UNITED THERAPEUTICS CORPORATION27.66%8 680
Brand Portfolio
ADDEX THERAPEUTICS
ADDEX THERAPEUTICS
» More brands of Addex Therapeutics Ltd